The OlympiA study defined high risk for HER2- early-stage breast cancer patients as four pathologically confirmed positive lymph nodes or a CPS + EG score of three or higher, in conjunction with adjuvant and neoadjuvant therapy, respectively [11]. The gene discussed is ERBB2; the disease is breast carcinoma.